(3-bromophenyl)(4-difluoromethoxyphenyl)methanone | 1398519-64-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3-bromophenyl)(4-difluoromethoxyphenyl)methanone
• 英文别名: (3-Bromophenyl)-[4-(difluoromethoxy)phenyl]methanone；(3-bromophenyl)-[4-(difluoromethoxy)phenyl]methanone
• CAS: 1398519-64-6
• 化学式: C₁₄H₉BrF₂O₂
• 分子量: 327.125
• InChiKey: YAFZWHNWZSQSDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (3-bromophenyl)(4-difluoromethoxyphenyl)methanone 、 甲基三苯基溴化膦 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以2.35 g的产率得到1-bromo-3-(1-(4-(difluoromethoxy)phenyl)vinyl)benzene
  参考文献：
  名称：

  Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer’s Disease

  摘要：

  A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human beta-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound ha resulted in a significant reduction of CNS A beta 40 in naive rats.

  DOI：

  10.1021/jm300598e
• 作为产物：
  描述：

  3-溴-4'-甲氧基苯甲酮 在 三溴化硼 、 potassium carbonate 作用下， 以 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 (3-bromophenyl)(4-difluoromethoxyphenyl)methanone
  参考文献：
  名称：

  Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer’s Disease

  摘要：

  A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human beta-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound ha resulted in a significant reduction of CNS A beta 40 in naive rats.

  DOI：

  10.1021/jm300598e

文献信息

• Structure- and Property-Based Design of Aminooxazoline Xanthenes as Selective, Orally Efficacious, and CNS Penetrable BACE Inhibitors for the Treatment of Alzheimer’s Disease
  作者：Hongbing Huang、Daniel S. La、Alan C. Cheng、Douglas A. Whittington、Vinod F. Patel、Kui Chen、Thomas A. Dineen、Oleg Epstein、Russell Graceffa、Dean Hickman、Y.-H. Kiang、Steven Louie、Yi Luo、Robert C. Wahl、Paul H. Wen、Stephen Wood、Robert T. Fremeau

  DOI：10.1021/jm300598e

  日期：2012.11.8

  A structure- and property-based drug design approach was employed to identify aminooxazoline xanthenes as potent and selective human beta-secretase inhibitors. These compounds exhibited good isolated enzyme, cell potency, and selectivity against the structurally related aspartyl protease cathepsin D. Our efforts resulted in the identification of a potent, orally bioavailable CNS penetrant compound that exhibited in vivo efficacy. A single oral dose of compound ha resulted in a significant reduction of CNS A beta 40 in naive rats.